Takeda Pharmaceutical (TAK) has teamed up with the Indonesian government to build the country's plasma ecosystem and expand access to plasma-derived therapies, the company said over the weekend.
Under the deal, the company secured a plasma fractionation license from the country's Ministry of Health and will invest up to $30 million in a two-year pilot program to open plasma donation centers as part of a multi-year plan to develop large-scale plasma collection and manufacturing capabilities.
The first donation center is expected to open in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments